Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4914 |
Name | esophagus adenocarcinoma |
Definition | An esophageal carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer esophageal carcinoma esophagus adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | Adavosertib + Radiotherapy | esophagus adenocarcinoma | sensitive | detail... |
TP53 mutant | Adavosertib | esophagus adenocarcinoma | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | esophagus adenocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | esophagus adenocarcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | esophagus adenocarcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | esophagus adenocarcinoma | sensitive | detail... |
RET fusion | Selpercatinib | esophagus adenocarcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | esophagus adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01196390 | Phase III | Carboplatin + Paclitaxel + Trastuzumab Carboplatin + Paclitaxel | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT01307956 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer | Terminated | USA | 0 |
NCT01490749 | Phase I | Carboplatin + Cetuximab + Everolimus + Paclitaxel | Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | Completed | USA | 0 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01747551 | Phase II | Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | Completed | USA | 0 |
NCT01774851 | Phase II | MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Terminated | USA | 0 |
NCT01913639 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | Completed | USA | 0 |
NCT02013154 | Phase I | DKN-01 + Paclitaxel | A Study of DKN-01 in Combination With Paclitaxel | Completed | USA | 0 |
NCT02016534 | Phase II | AMG 337 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 8 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02138929 | Phase I | Everolimus + Sonidegib | LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | Completed | USA | 0 |
NCT02234180 | Phase II | Regorafenib | Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy | Terminated | USA | 0 |
NCT02234596 | Phase II | Nintedanib | Nintedanib in Patients With Advanced Esophagogastric Cancer | Completed | USA | 0 |
NCT02241720 | Phase II | Regorafenib | Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers | Terminated | USA | 0 |
NCT02283359 | Phase I | Irinotecan + Selinexor | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | Terminated | USA | 0 |
NCT02317991 | Phase II | Nab-paclitaxel + Ramucirumab | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | Completed | USA | 0 |
NCT02389751 | Phase I | Carboplatin Paclitaxel Ganetespib | A Study of Ganetespib in Combination With Chemoradiation | Completed | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | 8 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02530437 | Phase Ib/II | Taladegib Carboplatin + Paclitaxel | A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | Terminated | USA | 0 |
NCT02559687 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | Completed | 0 | |
NCT02564263 | Phase III | Pembrolizumab Docetaxel + Irinotecan + Paclitaxel | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Completed | 0 | |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02639065 | Phase II | Durvalumab | A Study of Durvalumab (MEDI4736) in Esophageal Cancer | Completed | USA | 0 |
NCT02642809 | Phase I | Pembrolizumab | Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers | Completed | USA | 0 |
NCT02678182 | Phase II | Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) | Recruiting | GBR | 0 |
NCT02954536 | Phase II | Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | Completed | USA | 0 |
NCT02962063 | Phase Ib/II | Carboplatin + Durvalumab + Paclitaxel | Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | Recruiting | USA | 0 |
NCT02971956 | Phase II | Pembrolizumab | A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT02998268 | Phase II | Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03064490 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) | Active, not recruiting | USA | 0 |
NCT03122548 | Phase II | CRS-207 + Pembrolizumab | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | Terminated | USA | 0 |
NCT03132922 | Phase I | ADP-A2M4 cells | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03165994 | Phase II | APX005M + Carboplatin + Paclitaxel | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | Active, not recruiting | USA | 0 |
NCT03189719 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 19 |
NCT03193918 | Phase I | Crenolanib + Paclitaxel + Ramucirumab | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | Completed | USA | 0 |
NCT03196232 | Phase II | Epacadostat + Pembrolizumab | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | Completed | USA | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Active, not recruiting | USA | 0 |
NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Active, not recruiting | FRA | BEL | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03437200 | Phase II | Nivolumab Ipilimumab + Nivolumab | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) | Terminated | FRA | ESP | 0 |
NCT03443856 | Phase II | Ipilimumab + Nivolumab | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE) | Active, not recruiting | ITA | GBR | FRA | ESP | DEU | 4 |
NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Suspended | USA | 0 |
NCT03610711 | Phase Ib/II | Nivolumab + Relatlimab Nivolumab | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) | Recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | GBR | FRA | ESP | 2 |
NCT03777813 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (ARION) | Recruiting | FRA | 0 |
NCT03783936 | Phase II | Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | Unknown status | USA | 0 |
NCT03784326 | Phase I | Atezolizumab + Fluorouracil + Oxaliplatin | Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT03840967 | Phase II | Niraparib | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03997448 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | Terminated | USA | 0 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Recruiting | USA | AUS | 4 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04089904 | Phase II | Pembrolizumab | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Recruiting | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Active, not recruiting | USA | FRA | ESP | DEU | BEL | 3 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Recruiting | USA | AUS | 3 |
NCT04159974 | Phase II | Durvalumab Durvalumab + Tremelimumab | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE) | Recruiting | DEU | 0 |
NCT04171141 | Phase I | PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Recruiting | USA | AUS | 1 |
NCT04210115 | Phase III | Cisplatin + Fluorouracil + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | Recruiting | USA | ITA | GBR | FRA | DEU | CAN | BEL | 18 |
NCT04391049 | Phase I | Carboplatin + OBP-301 + Paclitaxel | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | Active, not recruiting | USA | 0 |
NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Recruiting | USA | 1 |
NCT04460937 | Phase I | Adavosertib | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers | Active, not recruiting | USA | 0 |
NCT04510285 | Phase II | Pembrolizumab + Trastuzumab | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | Terminated | USA | 0 |
NCT04594811 | Phase II | Nivolumab Nivolumab + NT-I7 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Active, not recruiting | USA | 1 |
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Active, not recruiting | USA | ESP | CAN | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of BND-22 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04757363 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Regorafenib | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | Active, not recruiting | USA | 0 |
NCT04900818 | Phase I | TJ033721 | Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT04921904 | Phase Ib/II | Abemaciclib + Ramucirumab | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | Not yet recruiting | USA | 0 |
NCT04929392 | Phase II | Carboplatin + Lenvatinib + Paclitaxel + Pembrolizumab | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | Recruiting | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Recruiting | USA | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 9 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | 1 | |
NCT05135845 | Phase II | Capmatinib + Spartalizumab | Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (METIMGAST) | Suspended | FRA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05152147 | Phase III | Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + ZW25 Cisplatin + Fluorouracil + Tislelizumab + ZW25 Capecitabine + Oxaliplatin + Tislelizumab + ZW25 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) | Recruiting | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 25 |
NCT05187182 | Phase I | CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | Recruiting | USA | 0 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Recruiting | USA | 0 |
NCT05245760 | Phase II | Tislelizumab | ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER) | Withdrawn | USA | 0 |
NCT05329766 | Phase II | AB680 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Zimberelimab Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) | Recruiting | USA | FRA | 1 |
NCT05480384 | Phase II | Nivolumab + Trastuzumab deruxtecan | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2- Positive Cancers of the Esophagus and Gastroesophageal Junction | Not yet recruiting | USA | 0 |
NCT05568095 | Phase III | AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Capecitabine + Oxaliplatin + Zimberelimab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221) | Recruiting | USA | 1 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Recruiting | USA | 1 |
NCT05651594 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Propranolol | Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma | Recruiting | USA | 0 |
NCT05713838 | Phase II | Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Durvalumab | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | Not yet recruiting | DEU | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |